A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa, is set to begin next week, World Health Organization officials said Wednesday.
The clinical trial — which will test both Gilead Sciences’ antiviral drug remdesivir and MappBio’s monoclonal antibody MBP-134 — will be conducted in the Democratic Republic of the Congo. The trial aims to assess the efficacy of these therapies against this specific strain of Ebola, as well as explore the potential benefits of their combined use in treating the disease. As the outbreak continues to escalate, the outcomes of this trial could have significant implications for future treatment protocols and regulatory strategies in managing Ebola outbreaks, highlighting the urgent need for effective therapeutic options in high-risk regions.
Get started today with Solo access →
